Abbott Laboratories (ABT) Landmark study shows Libre technology helps people with Type 2 diabetes on basal insulin improve glucose management
Abbott Laboratories (NYSE: ABT) FY 2026 Other Release
62 articles, transcripts, and reports
Abbott Laboratories (NYSE: ABT) FY 2026 Other Release
Abbott Laboratories (NYSE: ABT) FY 2026 Other Release
Abbott Laboratories (NYSE: ABT) Sec Form 8K
Abbott Laboratories (NYSE: ABT) Sec Form 8K
Abbott Laboratories (NYSE: ABT) Sec Form 10K
Abbott Laboratories (NYSE: ABT) Sec Form 8K
Abbott Laboratories (NYSE: ABT) Q2 2026 Dividend Update
Abbott Laboratories (NYSE: ABT) Q4 2025 Earnings Conference
Abbott Laboratories (NYSE: ABT) Q4 2025 Earnings Call dated Jan. 22, 2026 Corporate Participants: Michael Comilla — Vice President of...
Abbott (NYSE: ABT) on Friday reported positive data from studies evaluating the safety and effectiveness of its Volt Pulsed Field...